Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01975935 · ClinicalTrials.gov registry record · Phase 2
Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic Patients
A Phase 2 study, sponsored by University of Michigan.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT01975935 is a Phase 2 study that has completed, run by University of Michigan. The registered enrollment target is 42 participants.
The verdict
NCT01975935, a Phase 2 study, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
This study involves research about an investigational medicine called Amlexanox. The reason for this study is to find out how Amlexanox can improve type 2 diabetes, insulin resistance, obesity and non-alcoholic fatty liver disease (NAFLD). In this study, Amlexanox is considered to be investigational (not approved by the Food and Drug Administration \[FDA\]) for type 2 diabetes, insulin resistance, obesity and non-alcoholic fatty liver disease (NAFLD). This is a placebo controlled study. There is a 50-50 chance that the patient may either receive the study drug, Amlexanox, or a placebo (sugar pill). Neither the patient or the study doctors will know if the patient is receiving the study drug or placebo.
Interventions
- DRUG Placebo
- DRUG Amlexanox
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2014-01 |
| Est. Completion | 2017-08-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01975935
The ClinicalTrials.gov registry entry for NCT01975935 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01975935 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01975935 about?
NCT01975935 is a clinical study titled "Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic Patients". This study involves research about an investigational medicine called Amlexanox. The reason for this study is to find out how Amlexanox can improve type 2 diabetes, insulin resistance, obesity and non-alcoholic fatty liver disease (NAFLD). In this study, Amlexanox is considered to be investigational...
What is the current status of trial NCT01975935?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2014-01. Estimated completion is 2017-08-18.
What interventions are being tested in trial NCT01975935?
The interventions under investigation include: Placebo (DRUG), Amlexanox (DRUG).
Who is sponsoring clinical trial NCT01975935?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.